Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. Thi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Commun
Main Authors: Formisano, Luigi, Lu, Yao, Servetto, Alberto, Hanker, Ariella B., Jansen, Valerie M., Bauer, Joshua A., Sudhan, Dhivya R., Guerrero-Zotano, Angel L., Croessmann, Sarah, Guo, Yan, Ericsson, Paula Gonzalez, Lee, Kyung-min, Nixon, Mellissa J., Schwarz, Luis J., Sanders, Melinda E., Dugger, Teresa C., Cruz, Marcelo Rocha, Behdad, Amir, Cristofanilli, Massimo, Bardia, Aditya, O’Shaughnessy, Joyce, Nagy, Rebecca J., Lanman, Richard B., Solovieff, Nadia, He, Wei, Miller, Michelle, Su, Fei, Shyr, Yu, Mayer, Ingrid A., Balko, Justin M., Arteaga, Carlos L.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435685/
https://ncbi.nlm.nih.gov/pubmed/30914635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09068-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki